. The enzyme that mediates this Complement-mediated inactivation of retroviruses in transfer is ␣1-3galactosyl transferase, a protein that is human serum triggered by anti-Gal represents a unique absent in Old World primates. Transcription from the type of natural immunity. Antibodies are normally con-␣1-3galactosyl transferase gene in Old World primates sidered to be an element of acquired immunity elicited is undetectable, and nonsense mutations are present in response to a specific foreign antigen. In contrast, within the coding region of some species. The presence anti-Gal is preformed and recognizes a carbohydrate of a functional ␣1-3galactosyl transferase in New World moiety that is present on a variety of viruses. monkeys indicates that this gene was inactivated after Prior to identification of anti-Gal, several studies rethe divergence of Old and New World primates approxiported naturally occurring antibody that recognized enmately 40 million years ago. It has been speculated that velope glycoproteins from various type C retroviruses.
example, envelope glycoproteins were only targeted by
The occurrence of zoonotic diseases does not rule out a role for anti-Gal in natural immunity against some antibody when the retroviruses were grown in non-Old World primate cells. In addition, serum proteins from viruses. Effective elimination of viruses expressing the ␣-galactosyl epitope is likely to be dependent on several New World primates or other mammalian species, but not Old World primates, shared the envelope glycoprofactors including route of transmission and viral dose. For example, viruses introduced through aerosol transtein determinants recognized by the natural antibody. These data suggest that the ␣-galactosyl epitope may mission will not initially encounter high-titer anti-Gal IgG. Although gamma A class secretory anti-Gal may be enbe commonly associated with the envelopes of many different retroviruses when passaged through cells that countered during this mode of transmission, IgA is a poor activator of complement and its binding has been express a functional ␣1-3galactosyl transferase (references can be found in Barbacid et al., 1980) . shown to actually protect some bacteria from complement lysis (Hamadeh et al., 1995) . In addition, if inactivaIn addition to retroviruses, other enveloped viruses contain proteins and/or lipids that bear the ␣-galactosyl tion of a particular virus by anti-Gal is complement dependent, concentration of complement at the site of epitope. The envelope of the eastern equine encephalitis virus has recently been shown to incorporate ␣-galactoviral entry may play a critical role. Finally, the size of the initial dose of virus could determine the difference syl modified glycoproteins when propagated through murine but not Old World primate cells (Repik et al., between pathogenesis or viral clearance. If a single virion escapes anti-Gal-mediated inactivation and is am-1994). Other enveloped viruses, including the lymphocytic choriomeningitis virus (LCMV) and Newcastle displified in a human cell, it will no longer express the ␣-galactosyl epitope and could more readily spread to ease virus, acquire sensitivity to human serum when passaged through cells that express ␣1-3galactosyl other cells. By the same token, once a virus successfully infects one individual, transmission to other humans will transferase (Welsh, 1977) . Conversely, LCMV grown in human cells or ␣-galactosyl epitope-deficient baby not be subject to inactivation through this mechanism. Implications in Retroviral-Mediated Gene Therapy hamster kidney cells is completely resistant to human serum killing. Although the ␣-galactosyl epitope has not
The role of the ␣-galactosyl epitope in serum killing of retroviruses has important implications in the field of been identified on the surface of these viruses, the parallel between serum sensitivity and cell passage history retroviral-mediated gene therapy. Although the transfer of genes via retroviral particles has proven successful strongly suggests its presence.
The potential importance of human anti-Gal in providex vivo, gene transfer in vivo has been primarily restricted to nonprimate species. One of the major obstaing natural immunity against enveloped viruses originating from animal species that express the ␣-galactosyl cles to in vivo retroviral gene transfer in Old World primates, including humans, is the rapid complementepitope is not known. Conservation of high-titer antiGal expression in Old World primates, including humans, mediated inactivation of murine-derived retroviruses in primate blood. The observation that retroviral inactivasuggests a critical function for this immunoglobulin. However, the occurrence of human zoonotic diseases tion is mediated through recognition of the ␣-galactosyl epitope has thus prompted attempts to prevent incorposuch as influenza, rabies, and vesicular stomatitis suggests that this antibody is not a strong impediment to ration of this carbohydrate structure into viral envelopes. One strategy that has recently been employed to gencross-species transfer of all viruses. Furthermore, agammaglobulinemia patients, who should lack this erate serum-resistant retroviruses involves the manipulation of currently available high-titer retroviral producer type of immunological barrier, do not appear to show a higher incidence of such zoonotic infections.
cells. This strategy is based on previous observations showing that competition between glycosyl transfer-1995). It is likely that survival of transplanted xenogeneic cells in tissues that are exposed to higher levels of antiases for a common acceptor can determine which terminal glycosidic residues are added. The N-acetyllactobody and complement can also be potentiated by manipulation of the ␣-galactosyl epitope. saminyl group (shown in Figure 1) 
